Form 4: Moderna Director Elizabeth Nabel Reports Stock Transactions

Moderna Director Elizabeth G. Nabel has reported transactions involving restricted stock units and common stock.

Summary

• Elizabeth G. Nabel, a Director at Moderna, Inc., reported transactions on April 30, 2026.
• These transactions involved the vesting of 16,233 Restricted Stock Units (RSUs) into common stock.
• Following these transactions, Ms. Nabel beneficially owns 19,317 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard disclosure of insider stock vesting and subsequent ownership, without indicating new investment or divestment decisions.

Positives

• Vesting of restricted stock units indicates that performance or time-based conditions have been met, potentially aligning management interests with shareholders.
• The reporting person, a Director, continues to hold a significant number of shares (19,317) after the transaction.

Negatives

• The filing details a disposition of 16,233 shares of common stock, which could be interpreted as a sale, although the context suggests it's a conversion from vested RSUs.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This filing is typical for a company like Moderna in the biotechnology sector.

Stakeholder Impact

• Shareholders gain transparency into the holdings of Director Elizabeth G. Nabel following the vesting of her restricted stock units.

Key Dates

Keywords

Moderna, MRNA, Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Elizabeth G. Nabel